Clinical Trials

A Study of Intra-operative Imaging in Women With Ovarian Cancer

Conditions: Ovarian Cancer, Ovarian Carcinoma

Interventions: Intravenous Indocyanine Green/ICG injection, PINPOINT endoscopic fluorescence imaging system, Endoscopy

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal

Interventions: AZD5335, Itraconazole

Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for Cancer

Conditions: Sarcopenia, Pancreatic Cancer

Interventions: Prehabilitation program, Oral Impact

Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer

Conditions: Pancreatic Cancer Non-resectable

Interventions: Stereotactic Body Radiotherapy (SBRT) with maintenance therapy, Maintenance therapy

PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence

Conditions: Colorectal Cancer

Interventions: Regorafenib, Panitumumab

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Conditions: Colorectal Cancer

Interventions: Fruquintinib

Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

Conditions: Colorectal Cancer Metastatic

Interventions: Capecitabine, Bevacizumab, Trifluridine/Tipiracil

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Xaluritamig

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Conditions: Prostate Carcinoma, Benign Prostatic Hyperplasia

Interventions: Merit Medical Embospheres, Radiation Therapy

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → vs Pembrolizumab Plus ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Conditions: Non-small Cell Lung Cancer

Interventions: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Conditions: Neoplasms

Interventions: Alectinib, Crizotinib

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer

Interventions: Ubamatamab, REGN7075, Sarilumab

Endocrine TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Conditions: Breast Neoplasm Female

Interventions: CDK 4/6 inhibitor, Non-Steroidal Aromatase Inhibitor, Fulvestrant

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation → Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Conditions: Breast Neoplasms, Breast Cancer

Interventions: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib

Evolutionary Clinical TrialA research study that tests a medical intervention in human volunteers.Click for full explanation → for Novel BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation →-Driven Therapies

Conditions: Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma

Interventions: SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen

Contrast-Free Magnetic Resonance Imaging for Breast Disease

Conditions: Breast Cancer, Breast Diseases

Interventions: Outpatient MRI

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Conditions: Acute Lymphoblastic Leukemia, B-All

Interventions: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Conditions: Metastatic Castration-Resistant Prostate Cancer

Interventions: PF-06821497, Placebo, Enzalutamide

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma

Interventions: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor

Interventions: IPN01194, IPN01194

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Conditions: Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8

Interventions: Ipilimumab, Valemetostat

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

Interventions: Aurora A Kinase Inhibitor LY3295668, Osimertinib

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Conditions: Small Cell Lung Carcinoma

Interventions: Durvalumab

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Conditions: Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer

Interventions: Stereotactic body radiation therapy (SBRT), PDS01ADC, M7824

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Conditions: Breast Cancer

Interventions: Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Interventions: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Conditions: Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: ponsegromab, placebo

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Conditions: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer

Interventions: PTM-101

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)

Interventions: PF-07799544, PF-07799933

Study of Revumenib in Combination With Intensive ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationA change in DNA sequence that can drive cancer development.Click for full explanation →

Conditions: Acute Myeloid Leukemias

Interventions: Revumenib, Placebo, Intensive ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Regimen

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Conditions: Advanced Solid Tumors

Interventions: BAY3375968, Pembrolizumab

Study for AZD4360 in Participants With Advanced Solid Tumours

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

Interventions: AZD4360

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Conditions: Acute Myeloid Leukemia

Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)

Interventions: Mervometostat (PF-06821497), Enzalutamide, Itraconazole

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome

Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, MutationA change in DNA sequence that can drive cancer development.Click for full explanation → Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Conditions: Extensive Stage Lung Small Cell Carcinoma

Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma

Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Conditions: Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute

Interventions: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related

Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax

Testing the Combination of DS-8201a and Olaparib in HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Conditions: Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm

Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Trastuzumab Deruxtecan